Volition is a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. Volition was established in 2010 when our team saw a chance to bring long-established ELISA technology with cutting-edge nucleosome detection technology and analysis techniques. Current cancer diagnosis frequently involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q™ technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing. It is a simple solution to the challenging problem of early cancer diagnosis.